| Lu, Ying |
| Recruiting | 3 | 240 | RoW | Equecabtagene Autoleucel Injection, FUCASO, Daratumumab, Pomalidomide, Bortezomib, Dexamethasone | Nanjing IASO Biotechnology Co., Ltd. | Multiple Myeloma | 08/27 | 12/30 | | |
NCT06520176: Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients |
|
|
| Recruiting | 3 | 99 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, Pegfilgrastim, PEG-rhG-CSF, Cyclophosphamide, Cy, G-CSF, Granulocyte Colony Stimulating Factor | The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, The Central Hospital of Lishui City, Jinhua People's Hospital, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital | Multiple Myeloma, Hematopoietic Stem Cell Mobilization | 12/26 | 12/26 | | |
NCT06520163: Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma |
|
|
| Recruiting | 3 | 99 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF, G-CSF, CHOP, Hyper-CVAD, ID-MTX + Ara-C, DA-EPOCH, GDP, GDPE, ICE, DICE | The Affiliated People's Hospital of Ningbo University, First Affiliated Hospital of Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Jinhua People's Hospital, The Central Hospital of Lishui City, Shaoxing People's Hospital, Shaoxing Second Hospital, Zhejiang Provincial Tongde Hospital, Taizhou Hospital, Dongyang People's Hospital, Affiliated Hospital of Jiaxing University, Huizhou Municipal Central Hospital, Second Affiliated Hospital of Wenzhou Medical University, Ningbo Medical Center Lihuili Hospital, Jinhua Municipal Central Hospital | Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization | 12/26 | 12/26 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
NCT05780372: Reduced Volume of Neck Prophylactic Irradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 474 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy | Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Chongqing University Cancer Hospital, Dongguan People's Hospital, LiuZhou People's Hospital | Nasopharyngeal Carcinoma, Radiotherapy; Complications | 05/25 | 05/28 | | |
NCT05084027: Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT |
|
|
| Recruiting | 2 | 50 | RoW | venetoclax combining with fludarabine and melphalan | First Affiliated Hospital of Zhejiang University, Sir Run Run Shaw Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang Provincial People's Hospital, The affiliated people's hospital of Ningbo University, First Affiliated Hospital of Wenzhou Medical University, Ningbo Hospital of Zhejiang University, The First Affiliated Hospital of Zhejiang Chinese Medical University | Hematologic Malignancy, Older Patients, Allogeneic Hematopoietic Stem Cell Transplantation | 09/22 | 09/24 | | |
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
|
|
| Recruiting | 2 | 40 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 10/25 | 04/26 | | |
NCT06455410: GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 216 | RoW | GP, Adebrelimab, concurrent chemoradiotherapy (CCRT) | Sun Yat-sen University | Nasopharyngeal Carcinoma | 06/26 | 06/28 | | |
NCT03118986: RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy |
|
|
| Recruiting | 2 | 200 | Canada, US, RoW | Olanzapine, Placebo Oral Tablet | The Hospital for Sick Children, University of California, San Francisco, Children's Mercy Hospital Kansas City, St. Justine's Hospital, Columbia University, Medical University of South Carolina, CancerCare Manitoba, University of North Carolina, Chapel Hill, Nationwide Children's Hospital | Vomiting in Infants and/or Children, Nausea, Hematopoietic System--Cancer, Oncology | 03/25 | 04/25 | | |
NCT05422066: Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma |
|
|
| Recruiting | 2 | 50 | RoW | Selinexor, ATG-010, Xpovio, Rituximab, RiTUXimab Injection, Cyclophosphamide, Cyclophosphamide Injection, Doxorubicin, Doxorubicin Hydrochloride, Vincristine, Vincristine Injection, Prednisone, Prednisone Oral Product | Li Zhiming, Antengene Corporation | DLBCL Germinal Center B-Cell Type | 07/25 | 12/25 | | |
|
NCT05842512: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH |
|
|
| Recruiting | 2 | 40 | RoW | ADI-PEG20, Pegargiminase, Placebo | Polaris Group | Nonalcoholic Steatohepatitis (NASH) | 12/27 | 01/28 | | |
NCT02617407: Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients |
|
|
| Completed | 1 | 44 | US | Livionex® Dental Gel, Edathamil, PreviDent 5000 plus/Tom's of Maine Children's toothpaste, Over the counter toothpaste, Kolibree Toothbrush | University of California, San Francisco | Dental Plaque | 01/20 | 01/20 | | |
NCT05528887: Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies |
|
|
| Recruiting | 1 | 10 | RoW | Autologous CAR-T cells, Fludarabine, Fludara, Cyclophosphamide, Cytoxan | The Affiliated People's Hospital of Ningbo University, UTC Therapeutics Inc. | Relapsed/Refractory Hematological Malignancies, Lymphoma, Myeloma, Leukemia | 06/24 | 06/26 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT05510089: Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies |
|
|
| Recruiting | N/A | 62 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF | The Affiliated People's Hospital of Ningbo University | Hematological Malignancy | 05/24 | 12/24 | | |
2022-YAN-030, NCT05536154: Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies |
|
|
| Recruiting | N/A | 68 | RoW | Etoposide, VP-16, Cytarabine, Ara-C, PEG-rhG-CSF | The Affiliated People's Hospital of Ningbo University | Lymphoma, Multiple Myeloma | 06/24 | 10/24 | | |
NCT05589337: Baduanjin Training for Depression and Anxiety Patients |
|
|
| Recruiting | N/A | 120 | RoW | Baduanjin, Eight-section Brocade, Health education | Shanghai University of Traditional Chinese Medicine, Shanghai Mental Health Center | Depression Symptoms, Anxiety Symptoms | 06/24 | 12/24 | | |
NCT05717790: Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma |
|
|
| Recruiting | N/A | 288 | RoW | Nimotuzumab, h-R3, BIOMAb EGFR, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Fourth Affiliated Hospital of Guangxi Medical University, People's Hospital of Baise, Second Affiliated Hospital of Guangzhou Medical University, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin Medical University, China, LiuZhou People's Hospital, The First People's Hospital of Qinzhou, Wuzhou Red Cross Hospital, Affiliated Hospital of Youjiang Medical University for Nationalities | Nasopharyngeal Carcinoma by AJCC V8 Stage | 11/24 | 11/27 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT05355675: The Association of Microbiota Composition With cGVHD After Allo-HSCT |
|
|
| Recruiting | N/A | 300 | RoW | blood sample, stool sample | First Affiliated Hospital of Zhejiang University | Hematopoietic Stem Cell Transplantation, Hematologic Malignancy, Chronic Graft-versus-host-disease, Complication | 05/25 | 05/25 | | |
NCT05940480: TCM Daoyin Therapy in Individuals At-risk for COPD |
|
|
| Recruiting | N/A | 60 | RoW | TCM Daoyin, Qigong, Health education | Shanghai University of Traditional Chinese Medicine, Changzheng Community Health Service Center of Putuo District, Shanghai | Chronic Obstructive Pulmonary Disease, Lung Diseases, Obstructive | 06/27 | 12/27 | | |
| Liu, Hong |
| Recruiting | 4 | 1428 | RoW | Indomethacin SR, YINDUOMEIXIN, Placebos, sham | Peking Union Medical College Hospital | Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple | 06/28 | 06/30 | | |
NCT04134026: Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients |
|
|
| Not yet recruiting | 4 | 400 | RoW | HIF-PHI, Epoetin Alfa, Epogen | Second Xiangya Hospital of Central South University | Anemia in Incident Dialysis Patients | 10/23 | 10/24 | | |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT05173272: Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer |
|
|
| Recruiting | 3 | 286 | RoW | Neoadjuvant Therapy, Neoadjuvant chemotherapy combined with Serplulimab, CCRT, chemoradiation, Brachytherapy | Sichuan Cancer Hospital and Research Institute | Cervical Cancer | 12/27 | 12/28 | | |
NCT04736186: Prevention and Treatment of Pyrrolitinib-associated Diarrhea |
|
|
| Recruiting | 2/3 | 470 | RoW | Loperamide, Loperamide and golden bifid, Loperamide and montmorillonite powder | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 10/22 | 04/23 | | |
NCT04836520: SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. |
|
|
| Completed | 2 | 20 | RoW | SHR6390+anatrozole | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 02/23 | 03/23 | | |
NCT05641506: A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Yangzheng Xiaoji, Niraparib | Sichuan Cancer Hospital and Research Institute | Ovarian Cancer | 10/23 | 05/25 | | |
| Recruiting | 2 | 86 | RoW | Penpulimab, Anlotinib | Sichuan Cancer Hospital and Research Institute | Gynecological Cancer | 12/24 | 12/25 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
NCT06756321: A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy |
|
|
| Recruiting | 1 | 9 | RoW | anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells, Fludarabine, Cyclophosphamide | Affiliated Hospital of Nantong University, Shanghai First Song Biotechnology Co., LTD | Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia | 03/25 | 03/26 | | |
NCT04993794: Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV |
|
|
| Recruiting | N/A | 200 | RoW | XueBiJing Injection, Normal saline | Nanjing Medical University | Cardiovascular Disease, Aortic Dissection, Coronary Artery Disease, Valve Heart Disease, Congenital Heart Disease, Critical Illness | 12/22 | 12/22 | | |
PANDA V, NCT04444349: Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery |
|
|
| Recruiting | N/A | 500 | RoW | Coenzyme Q10, ubiquinone, Standard Medical Therapy | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University | Cardiovascular Disease | 12/25 | 12/25 | | |
NTU-CML-001, NCT05152537: FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia |
|
|
| Recruiting | N/A | 15 | RoW | | Affiliated Hospital of Nantong University | Folate, CML, Treatment-free Remission | 06/23 | 12/23 | | |
NCT04216823: Perfusion Index as an Objective Measure for Supraclavicular Brachial Plexus Block in Pediatric Patients |
|
|
| Completed | N/A | 104 | RoW | perfusion index | Tongji Hospital | Supraclavicular Brachial Plexus Block | 06/23 | 06/23 | | |
NCT05686863: Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children |
|
|
| Completed | N/A | 106 | RoW | Remimazolam, Rema, Esketamine, Esket, Propofol, Prop, remifentanil, remifen | Tongji Hospital | Drug Effect | 07/23 | 07/23 | | |
PANDA, NCT04699279: Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery ( III) |
|
|
| Recruiting | N/A | 300 | RoW | Rosuvastatin 10mg | Nanjing Medical University, Beijing Anzhen Hospital, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University, The Affiliated Hospital of Qingdao University Medical College | Acute Aortic Syndrome, Aortopathy | 12/24 | 12/24 | | |
NCT05487469: Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass |
|
|
| Recruiting | N/A | 200 | RoW | Thymosin Alpha1, Blank Control | Nanjing Medical University | Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy | 12/23 | 12/23 | | |
Panda II, NCT05339529: Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II) |
|
|
| Recruiting | N/A | 330 | RoW | Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-, Blank control | Nanjing Medical University, Beijing Anzhen Hospital, Second Affiliated Hospital of Nanchang University, Qilu Hospital of Shandong University, The First Affiliated Hospital of Guangzhou Medical University, Northern Jiangsu People's Hospital, Guangdong Provincial People's Hospital, First Affiliated Hospital of Kunming Medical University, Nanjing First Hospital, Nanjing Medical University, Shanghai East Hospital,Tongji University School of Medicine, The Seventh Affiliated Hospital of Xinjiang Medical University, Teda International Cardiovascular Hospital, Tianjin, China, First Affiliated Hospital Bengbu Medical College, West China Hospital Affiliated with Sichuan University | Acute Aortic Syndrome, Aortic Dissection Type a | 12/25 | 12/25 | | |
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program |
|
|
| Recruiting | N/A | 16000 | RoW | phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2 | Wuhan Union Hospital, China, Peking University First Hospital | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease | 12/23 | 12/24 | | |
NCT05881655: Slow Myopia Progression With Different Irradiance Light |
|
|
| Recruiting | N/A | 75 | RoW | Airdoc Red Lighting Device, Repeated Red Light, Low Lever Laser Therapy, Low Intensity Light Therapy, Photobiomodulation Therapy, Seconee, 650nm Red Light, Special Spectacles to Control Myopia, Essilor® Stellest™ Lenses, H.A.L.T lens | Beijing Airdoc Technology Co., Ltd., Shanghai Children's Medical Center | Myopia, Progressive | 05/24 | 12/25 | | |
PANDA VI, NCT06195267: Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Recruiting | N/A | 500 | RoW | Sivelestat, Blank control | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital | Aortic Dissection, Systemic Inflammatory Response Syndrome, Cardiovascular Diseases (CVD) | 12/25 | 12/25 | | |
COSEFDIP, NCT05755659: Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV. |
|
|
| Recruiting | N/A | 3000 | RoW | Fosaprepitant Dimeglumine for Injection, ShanQi®️ | Xijing Hospital | Neoplasms | 10/24 | 12/24 | | |
PANDA, NCT06707350: Protective Effect of RIPC Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery (Panda VII) |
|
|
| Not yet recruiting | N/A | 500 | RoW | Remote ischemic preconditioning (RIPC), sham condition (control group) | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University | Cardiopulmonary Bypass, Cardiovascular Diseases, Inflammatory Response During Cardiac Surgery | 12/25 | 12/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT06723366: Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery |
|
|
| Not yet recruiting | N/A | 120 | RoW | Angong Niuhuang Pill (ANP), Control (Standard treatment) | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, Capital Medicine University | Cardio-pulmonary Bypass, Cardiovascular Surgery, Cerebral Protection, Brain Injury | 12/25 | 12/25 | | |
PANDA, NCT06730802: Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting ( VIII) |
|
|
| Not yet recruiting | N/A | 400 | RoW | PCSK9 inhibitor, Statin | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital | Myocardial Ischaemic Syndrome, Coronary Heart Disease | 12/26 | 12/26 | | |
NCT01932411: Factors Affect Outcomes in Cardiovascular Surgery |
|
|
| Recruiting | N/A | 5000 | US | | University of California, Davis | Coronary Artery Disease, Valvular Diseases, Vascular Diseases | 02/25 | 07/25 | | |
| Recruiting | N/A | 2000 | RoW | Renal replacement therapy | Nanjing Medical University | Acute Kidney Injury, Cardiac Surgery | 12/25 | 12/25 | | |
NCT04398992: Additive Anti-inflammatory Action for Aortopathy & Arteriopathy |
|
|
| Enrolling by invitation | N/A | 10000 | RoW | observation | Nanjing Medical University, Beijing Anzhen Hospital | Acute Aortic Syndrome | 12/40 | 12/40 | | |
| Recruiting | N/A | 500 | RoW | soluble ST2 | Nanjing Medical University | Cardiovascular Disease | 12/25 | 12/25 | | |
PANDA IV, NCT04444362: Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Enrolling by invitation | N/A | 500 | RoW | Intestinal Microbiota Transplant (IMT) Capsules | Nanjing Medical University, Beijing Anzhen Hospital, Shanghai East Hospital of Tongji University, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University | Cardiovascular Disease, Cardiopulmonary Bypass | 12/25 | 12/25 | | |
PANDA, NCT06728605: Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Not yet recruiting | N/A | 400 | RoW | Enhanced External Counterpulsation (EECP), Sham Comparator | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University | Coronary Heart Disease (CHD), Cardio-pulmonary Bypass, Congestive Heart Failure Chronic, Cardiogenic Shock Acute | 12/25 | 12/25 | | |
BEST-BAO, NCT05631847: Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke |
|
|
| Recruiting | N/A | 336 | RoW | Endovascular treatment, Intravenous thrombolysis (Alteplase) | Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital | Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis, Alteplase, Endovascular Treatment | 01/27 | 05/27 | | |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
NCT05454397: A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients |
|
|
| Recruiting | N/A | 2000 | RoW | Observational study, no intervention | Nanfang Hospital of Southern Medical University, First Affiliated Hospital of Fujian Medical University, Yantai Yuhuangding Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, ZHEJIANG PROVINCE XIAOSHAN HOSPITAL, The First People's Hospital of Wenling, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical hospital, Henan Provincial People's Hospital, Zhongda Hospital Southeast University, The Second Affiliated Hospital of Harbin Medical University, The First people's Hospital of Kunshan, The 2nd Affiliated Hospital of Wenzhou Medical University, THE FIRST PEOPLE'S HOSPITAL OF JIASHAN, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Fujian Province Zhangzhou Hospital, People's Hospital of Chongqing, Nanjing Zijin Hospital, Hangzhou Red Cross Hospital, Wenzhou Hospital of Chinese Medicine, Kaifeng Central Hospital, First Affiliated Hospital of Guangxi Medical University, Zhongshan Hospital of Xiamen University, Xi'an Encephalopathy of Traditional Chinese Medicine Hospital, 903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, Xiangya Hospital of Central South University, Second Affiliated Hospital of Suzhou University, Tongji Hospital, The Affiliated Hospital o fQingdao University, The First Affiliated Hospital of Anhui Medical University, Yancheng Third People's Hospital, Linyi People's Hospital, Dongfang Hospital of Beijing University of Chinese Medicine, Affiliated Hospital of Qingdao University | Acute Stroke | 10/22 | 10/23 | | |
NCT04970264: A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer |
|
|
| Recruiting | N/A | 2000 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 03/23 | 03/25 | | |
| Recruiting | N/A | 300 | RoW | ECMO | Nanjing Medical University | Cardiogenic Shock, Cardiac Arrest, Heart Failure, Acute Respiratory Failure, Acute Respiratory Distress Syndrome | 12/25 | 12/25 | | |
| Recruiting | N/A | 1000 | RoW | Intra Aortic Balloon Pump | Nanjing Medical University | Acute Coronary Syndrome, Cardiogenic Shock, Coronary Artery Disease, Heart Failure, Left Ventricular Dysfunction, Low Cardiac Output Syndrome, Post-cardiac Surgery | 12/25 | 12/25 | | |
| Huang, He |
NCT05414006: Effect of S-ketamine in Cesarean Section Combined Anesthesia |
|
|
| Completed | 4 | 120 | RoW | S-ketamine, Patient controlled analgesia | The Second Affiliated Hospital of Chongqing Medical University | Postoperative Pain | 08/22 | 09/22 | | |
NCT05458453: An Exploratory Study of Esketamine in Patients After Thoracoscopic Surgery |
|
|
| Completed | 4 | 80 | RoW | Esketamine | The Second Affiliated Hospital of Chongqing Medical University | Esketamine, Thoracoscopic Surgery | 02/23 | 02/23 | | |
NCT05533281: Efficacy of Three Antiemetics in Preventing Nausea and Vomiting |
|
|
| Completed | 4 | 200 | RoW | tropisetron, metoclopramide, dexamethasone, normal saline | The Second Affiliated Hospital of Chongqing Medical University | Nausea and Vomiting | 10/23 | 11/23 | | |
NCT05265507: Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron |
|
|
| Recruiting | 4 | 480 | RoW | Glycopyrronium, Ondansetron | The Second Affiliated Hospital of Chongqing Medical University, Chongqing University Jiangjin Hospital, Chongqing Medical University, The People's Hospital of DAZU ，Chongqing, Xiangya Hospital of Central South University, West China Hospital, The People's Hospital of Tongliang District， Chongqing city, Chongqing Medical Center for Women and Children, Dianjiang People's Hospital of Chongqing, The Ninth People's Hospital of Chongqing, The People's Hospital of Yubei District of Chongqing city, Chongqing Yongchuan District People's Hospital, The First People's Hospital Of Chongqing Liang Jiang New Area, ChongGang General Hospital, The People's Hospital of Nanchuan, People's Hospital of Pengshui County, Yunyang people's Hospital, Chongqing Liangping District People's Hospital, Jiulongpo People's Hospital of chongqing, The People's Hospital of Qijiang District，Chongqing, University-Town Hospital of Chongqing Medical University, Chongqing Public Health Medical Center, CHONGQING BANAN HOSPITAL OF TCM | Postoperative Nausea and Vomiting | 05/23 | 05/23 | | |
NCT05331651: Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting |
|
|
| Completed | 4 | 480 | RoW | Glycopyrronium in Combination With Tropisetron, Normal Saline in Combination With Tropisetron | The Second Affiliated Hospital of Chongqing Medical University, Chongqing General Hospital, Chongqing Medical University, The People's Hospital of DAZU ，Chongqing, The People's Hospital of Chongqing Kaizhou District, Fuling Hospital affiliated to Chongqing University, Qianjiang Central Hospital of Chongqing, Stomatological Hospital of Chongqing Medical University, People's Hospital of Changshou Chongqing, The Ninth People's Hospital of Chongqing, The First People's Hospital Of Chongqing Liang Jiang New Area, People's Hospital of Xiushan County, Wushan County People's Hospital, Three Gorges Hospital of Chongqing University, First Affiliated Hospital of Chongqing Medical University, Department of Anesthesiology, Daping Hospital, Institute of Surgery Research, the Army Medical University, The People's Hospital of Nanchuan, Chongqing Traditional Chinese Medicine Hospital, People's Hospital of Shapingba District， Chongqing, Chongqing Liangping District People's Hospital, Chongqing Jiangbei Hospital of Traditional Chinese Medicine, People's Hospital of Chongqing Hechuan | Postoperative Nausea and Vomiting | 06/23 | 06/23 | | |
NCT06569953: Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: a Multicenter, Randomized, Double-blind, Controlled Clinical Trial |
|
|
| Recruiting | 4 | 284 | RoW | Liposomal bupivacaine, Bupivacaine Hydrochloride | The Second Affiliated Hospital of Chongqing Medical University, Chongqing General Hospital, LanZhou University, Xiangya Hospital of Central South University, Sichuan Provincial People's Hospital | Acute Pain, Chronic Pain, Postoperative Pain | 08/25 | 08/25 | | |
NCT02633176: Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 120 | RoW | Cetuximab, Erbitux, Cisplatin, Docetaxel, Taxotere, Capecitabine, Xeloda, Radiotherapy | Sun Yat-sen University, Chinese Southwest Oncology Group | Nasopharyngeal Carcinoma | 01/23 | | | |
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Canada, Japan, US, RoW | LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 08/23 | 05/27 | | |
TQ05105-III-01, NCT06682169: Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease |
|
|
| Recruiting | 3 | 182 | RoW | Rovadicitinib, Imatinib, Methotrexate, Mycophenolate mofetil, Rituximab | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Graft-versus-host Disease | 10/29 | 12/30 | | |
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
|
|
| Active, not recruiting | 3 | 440 | Europe, Canada, Japan, US, RoW | Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin | ADC Therapeutics S.A., ADC Therapeutics SA | Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | 06/25 | 06/28 | | |
|
|
|
| Active, not recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
ABSK021-201, NCT06186804: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) |
|
|
| Enrolling by invitation | 2 | 64 | RoW | ABSK021 | Abbisko Therapeutics Co, Ltd | cGvHD | 10/26 | 12/26 | | |
NCT04661020: CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 36 | RoW | CD19 CAR-T cells, CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Non-hodgkin Lymphoma,B Cell | 12/26 | 12/26 | | |
NCT04788472: Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph+ B-ALL |
|
|
| Completed | 2 | 28 | RoW | CAR-T cells targeting CD19 and CD22 | Zhejiang University, Yake Biotechnology Ltd. | B-Cell Acute Lymphoblastic Leukemia, Adult | 08/24 | 08/24 | | |
NCT05712083: A Study of BCMA CAR-T Cell Therapy for Newly Diagnosed Multiple Myeloma |
|
|
| Recruiting | 2 | 40 | RoW | BCMA CAR-T cells, BCMA CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Multiple Myeloma, New Diagnosis Tumor | 04/24 | 04/24 | | |
NCT06300320: A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease |
|
|
| Recruiting | 2 | 40 | RoW | TQ05105 tablets | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 10/25 | 04/26 | | |
NCT05827835: CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic Diseases |
|
|
| Recruiting | 2 | 30 | RoW | CD7 CAR-T cells injection, Allogeneic hematopoietic stem cell transplantation | Zhejiang University, Yake Biotechnology Ltd. | Hematologic Diseases, Neoplasms | 04/25 | 04/25 | | |
NCT04626908: Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma |
|
|
| Not yet recruiting | 1/2 | 18 | RoW | GC022F CAR-T cells, GC022F CAR-T cells injection | He Huang, Gracell Biotechnology Ltd. | Relapsed and Refractory, Lymphoid Hematological Malignancies | 06/22 | 06/23 | | |
FUMANBA-1, NCT05066646: A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 132 | RoW | CT103A | Nanjing IASO Biotherapeutics Co.,Ltd | Multiple Myeloma | 10/22 | 06/24 | | |
NCT04944043: A Study of TQ05105 in Patients With Chronic Graft Versus Host Disease |
|
|
| Active, not recruiting | 1/2 | 45 | RoW | TQ05105 Tablet | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Graft Versus Host Disease | 06/23 | 12/24 | | |
NCT06182696: OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM |
|
|
| Recruiting | 1/2 | 83 | RoW | OriCAR-017 | OriCell Therapeutics Co., Ltd. | Relapsed and/or Refractory Multiple Myeloma | 11/26 | 08/28 | | |
NCT06235229: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 110 | RoW | GC012F | Gracell Biotechnologies Ltd. | Multiple Myeloma | 03/26 | 06/26 | | |
NCT04740203: Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL |
|
|
| Recruiting | 1/2 | 50 | RoW | CAR-T cells targeting CD19 and CD22 | Zhejiang University, Yake Biotechnology Ltd. | B-Cell Acute Lymphoblastic Leukemia, Adult | 01/24 | 01/25 | | |
NCT04790747: Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions |
|
|
| Recruiting | 1/2 | 50 | RoW | CAR-T cells | Zhejiang University, Yake Biotechnology Ltd. | Hematological Malignancies | 03/24 | 03/25 | | |
NCT06118788: Phase I Clinical Study: BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1/2 | 24 | RoW | BG1805 | Guangzhou Bio-gene Technology Co., Ltd | Leukemia, Myeloid, Acute | 03/25 | 07/25 | | |
NCT04812691: CD19-targeted CAR T Cells （JWCAR029） for Primary Refractory Diffuse Large B Cell Lymphoma |
|
|
| Completed | 1 | 12 | RoW | JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells) | Shanghai Ming Ju Biotechnology Co., Ltd. | Diffuse Large B Cell Lymphoma | 06/21 | 04/23 | | |
NCT04516551: Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT |
|
|
| Recruiting | 1 | 18 | RoW | anti-CD19 allo-CAR-T cells | Xinqiao Hospital of Chongqing, Gracell Biotechnologies (Shanghai) Co., Ltd, First Affiliated Hospital of Zhejiang University, The Second Affiliated Hospital of Chongqing Medical University, The Affiliated Hospital Of Guizhou Medical University, The General Hospital of Western Theater Command, Chongqing University Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Tang-Du Hospital, 920th Hospital of Joint Logistics Support ForceFirst | Relapsed Adult ALL, B Cell Leukemia | 12/21 | 12/22 | | |
NCT04227015: A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy |
|
|
| Recruiting | 1 | 72 | RoW | CTA101, CTA101 UCAR-T cell injection | He Huang, Nanjing Bioheng Biotech Co., Ltd. | Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | 01/22 | 05/27 | | |
NCT04226989: A Study of CT-RD06 Cell Injection in Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancy |
|
|
| Recruiting | 1 | 72 | RoW | CT-RD06, CT-RD06 CAR-T cell injection | He Huang, Nanjing Bioheng Biotech Co., Ltd. | Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma | 02/22 | 05/24 | | |
NCT05030779: A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 9 | RoW | Assigned Interventions CD19/BCMA CAR T-cells | Zhejiang University, Yake Biotechnology Ltd. | Systemic Lupus Erythematosus, Autoimmune Diseases | 03/22 | 09/22 | | |
NCT04599556: Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy |
|
|
| Recruiting | 1 | 81 | RoW | anti-CD7 CAR-T | Zhejiang University, Yake Biotechnology Ltd. | CD7+ Acute Leukemia, CD7+ Lymphoma | 12/23 | 12/25 | | |
PG-CART-07-001, NCT05170568: PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies |
|
|
| Recruiting | 1 | 22 | RoW | T cell injection targeting CD7 chimeric antigen receptor, PA3-17 injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd., The First Affiliated Hospital of Zhengzhou University, Peking University People's Hospital, Union Hospital, affiliated with TongJi Medical College, HuaZhong University of Science and Technology, Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences), First Affiliated Hospital of Zhejiang University School of Medicine | CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies | 12/22 | 12/24 | | |
NCT04689204: A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies |
|
|
| Recruiting | 1 | 72 | RoW | CTA30X, CTA30X cell injection | He Huang, Nanjing Bioheng Biotech Co., Ltd. | Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma | 12/22 | 05/27 | | |
NCT04283006: A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies |
|
|
| Recruiting | 1 | 100 | RoW | CD20/CD22 dual Targeted CAR T-cells, CD20/CD22 dual Targeted CAR T-cells injection | He Huang, Yake Biotechnology Ltd. | Relapsed and Refractory, Lymphoid Hematological Malignancies | 05/23 | 05/28 | | |
NCT04532268: A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL |
|
|
| Recruiting | 1 | 72 | RoW | Humanized CD19 CAR-T cells, Humanized CD19 CAR-T cells injection | Zhejiang University, Yake Biotechnology Ltd. | Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma,B Cell | 08/23 | 08/26 | | |
NCT05731219: UTAA06 Injection in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
|
|
| Recruiting | 1 | 18 | RoW | B7-H3 target, CAR gene modified gdT cell injection, UTAA06 injection | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Relapsed/Refractory Acute Myeloid Leukemia | 09/23 | 09/25 | | |
NCT05846347: Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 15 | RoW | GC012F injection, CD19-BCMA CAR-T cells | Zhejiang University, Gracell Biotechnology Shanghai Co., Ltd. | CAR-T | 10/23 | 04/25 | | |
